UA82089C2 - Аплидин для лечения множественной миеломы - Google Patents
Аплидин для лечения множественной миеломы Download PDFInfo
- Publication number
- UA82089C2 UA82089C2 UAA200509530A UA2005009530A UA82089C2 UA 82089 C2 UA82089 C2 UA 82089C2 UA A200509530 A UAA200509530 A UA A200509530A UA 2005009530 A UA2005009530 A UA 2005009530A UA 82089 C2 UA82089 C2 UA 82089C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- aplidine
- activity
- multiple myeloma
- patients
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract description 116
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 title claims abstract description 100
- 108010049948 plitidepsin Proteins 0.000 title claims abstract description 97
- 229950008499 plitidepsin Drugs 0.000 title claims abstract description 97
- 208000034578 Multiple myelomas Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 89
- 230000000694 effects Effects 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 24
- 210000004881 tumor cell Anatomy 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229960003957 dexamethasone Drugs 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004180 plasmocyte Anatomy 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960003433 thalidomide Drugs 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010002156 Depsipeptides Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023774 Large cell lung cancer Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- -1 aplidine compound Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 101150117850 Krt80 gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101150110809 ORM1 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 101100045631 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TMA19 gene Proteins 0.000 description 1
- 101100345725 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mmi1 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000011229 conventional cytotoxic chemotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021184 main course Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 231100000483 muscle toxicity Toxicity 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001475 prostate lymphoma Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение касается применения аплидина для получения медикамента для лечения множественной миеломы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45412503P | 2003-03-12 | 2003-03-12 | |
PCT/GB2004/001062 WO2004080477A1 (en) | 2003-03-12 | 2004-03-12 | Aplidine for multiple myeloma treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
UA82089C2 true UA82089C2 (ru) | 2008-03-11 |
Family
ID=32990868
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200508279A UA83022C2 (ru) | 2003-03-12 | 2004-03-12 | Аплидин для комбинированной терапии лейкоза и лимфомы |
UAA200509530A UA82089C2 (ru) | 2003-03-12 | 2004-12-03 | Аплидин для лечения множественной миеломы |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200508279A UA83022C2 (ru) | 2003-03-12 | 2004-03-12 | Аплидин для комбинированной терапии лейкоза и лимфомы |
Country Status (13)
Country | Link |
---|---|
US (2) | US7576188B2 (ru) |
EP (1) | EP1620117A4 (ru) |
JP (1) | JP2006519848A (ru) |
KR (1) | KR20060002778A (ru) |
CN (3) | CN101579520A (ru) |
AU (1) | AU2004220451B2 (ru) |
CA (1) | CA2516572A1 (ru) |
MX (1) | MXPA05009741A (ru) |
NO (1) | NO20053947L (ru) |
NZ (1) | NZ541634A (ru) |
RU (1) | RU2341283C2 (ru) |
UA (2) | UA83022C2 (ru) |
WO (1) | WO2004080421A2 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
PL200922B1 (pl) * | 1999-11-15 | 2009-02-27 | Pharma Mar Sa | Zastosowanie aplidyny do wytwarzania kompozycji farmaceutycznej |
UA76718C2 (ru) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Противоопухолевые производные аплидина |
ATE299028T1 (de) | 2000-10-12 | 2005-07-15 | Pharma Mar Sa | Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin |
ES2312979T3 (es) | 2003-03-12 | 2009-03-01 | Dana-Farber Cancer Institute, Inc. | Aplidina para el tratamiento de mieloma multiple. |
CN101579520A (zh) * | 2003-03-12 | 2009-11-18 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
WO2007101235A2 (en) * | 2006-02-28 | 2007-09-07 | Pharma Mar, S.A. | Improved antitumoral treatments |
ITMI20070817A1 (it) * | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi |
WO2008135793A1 (en) * | 2007-05-04 | 2008-11-13 | Pharma Mar S.A. | Combination of aplidine and carboplatin in anticancer treatments |
US20100240595A1 (en) * | 2007-10-19 | 2010-09-23 | Pharma Mar ,S.A. | Improved Antitumoral Treatments |
EP2262523A1 (en) * | 2008-03-07 | 2010-12-22 | Pharma Mar S.A. | Improved anticancer treatments |
WO2010029158A1 (en) * | 2008-09-12 | 2010-03-18 | Pharma Mar, S.A. | Aplidine in the treatment of chronic myeloproliferative disorders |
CN104706599B (zh) * | 2013-12-11 | 2020-10-02 | 中国海洋大学 | 一种携带膜海鞘素化合物的冻干粉针剂 |
KR102511028B1 (ko) | 2016-03-15 | 2023-03-16 | 오리존 지노믹스 에스.에이. | 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물 |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950649A (en) * | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
DE3161556D1 (en) | 1980-09-12 | 1984-01-05 | Univ Illinois | Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them |
US4493796A (en) * | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
EP0220453B1 (de) * | 1985-09-20 | 1992-04-15 | Cernitin S.A. | Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung |
US4948791A (en) | 1989-04-10 | 1990-08-14 | The Board Of Trustees Of The University Of Illinois | Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum |
GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
US5018188A (en) | 1989-12-20 | 1991-05-21 | Motorola, Inc. | Microphone-controller with multifunction, single conductor |
DE4120327A1 (de) | 1991-06-20 | 1992-12-24 | Basf Ag | Neue peptide, ihre herstellung und verwendung |
US5482726A (en) * | 1992-07-14 | 1996-01-09 | Us Harvest Technologies Corporation | Method for reducing contamination of shellfish |
US5580871A (en) | 1992-11-20 | 1996-12-03 | The Dupont Merck Pharmaceutical Company | 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity |
US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
ES2102322B1 (es) | 1995-07-13 | 1998-03-01 | Pharma Mar Sa | Procedimiento de preparacion de didemnina a. |
US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
ES2135359T3 (es) | 1996-07-03 | 2002-05-16 | Paxton C G Ltd | Recipientes. |
PT956033E (pt) | 1996-10-24 | 2003-10-31 | Univ Illinois | SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A |
JP2001503746A (ja) | 1996-10-24 | 2001-03-21 | ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ | ジデムニン類似体の半合成法 |
US6034058A (en) * | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
JP4327260B2 (ja) * | 1997-05-07 | 2009-09-09 | フアルマ・マル・エセ・ア | L型カルシウムチャンネルエンハンサーとしてのアプリジン |
GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
GB9821975D0 (en) | 1998-10-08 | 1998-12-02 | Pharma Mar Sa | New cytotoxic alkaloids |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PL200922B1 (pl) * | 1999-11-15 | 2009-02-27 | Pharma Mar Sa | Zastosowanie aplidyny do wytwarzania kompozycji farmaceutycznej |
SE9904175D0 (sv) | 1999-11-18 | 1999-11-18 | Pharmacia & Upjohn Diag Ab | Assay device and use thereof |
NZ521844A (en) | 2000-04-07 | 2004-07-30 | Univ Pennsylvania | Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof |
AU6836301A (en) * | 2000-06-20 | 2002-01-02 | Idec Pharma Corp | Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
UA76718C2 (ru) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Противоопухолевые производные аплидина |
ATE299028T1 (de) * | 2000-10-12 | 2005-07-15 | Pharma Mar Sa | Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin |
AU9402401A (en) | 2000-10-12 | 2002-04-22 | Pharma Mar Sa | Treatment of cancers |
WO2002058688A1 (de) * | 2001-01-24 | 2002-08-01 | Mestex Ag | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen |
ATA13422001A (de) | 2001-08-23 | 2003-09-15 | Plasser Bahnbaumasch Franz | Maschine zur bearbeitung einer gleisbettung |
CA2462642A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Use of aplidine for the treatment of pancreatic cancer |
ES2312979T3 (es) | 2003-03-12 | 2009-03-01 | Dana-Farber Cancer Institute, Inc. | Aplidina para el tratamiento de mieloma multiple. |
CN101579520A (zh) | 2003-03-12 | 2009-11-18 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
-
2004
- 2004-03-12 CN CNA2009100039994A patent/CN101579520A/zh active Pending
- 2004-03-12 JP JP2006507125A patent/JP2006519848A/ja active Pending
- 2004-03-12 CN CNB2004800051794A patent/CN100409895C/zh not_active Expired - Fee Related
- 2004-03-12 US US10/546,750 patent/US7576188B2/en not_active Expired - Fee Related
- 2004-03-12 UA UAA200508279A patent/UA83022C2/ru unknown
- 2004-03-12 CA CA002516572A patent/CA2516572A1/en not_active Abandoned
- 2004-03-12 RU RU2005126819/15A patent/RU2341283C2/ru not_active IP Right Cessation
- 2004-03-12 EP EP04720399A patent/EP1620117A4/en not_active Withdrawn
- 2004-03-12 AU AU2004220451A patent/AU2004220451B2/en not_active Ceased
- 2004-03-12 WO PCT/US2004/007606 patent/WO2004080421A2/en active Application Filing
- 2004-03-12 MX MXPA05009741A patent/MXPA05009741A/es unknown
- 2004-03-12 CN CN2004800067241A patent/CN1761480B/zh not_active Expired - Lifetime
- 2004-03-12 KR KR1020057015665A patent/KR20060002778A/ko not_active Application Discontinuation
- 2004-03-12 NZ NZ541634A patent/NZ541634A/en not_active IP Right Cessation
- 2004-12-03 UA UAA200509530A patent/UA82089C2/ru unknown
-
2005
- 2005-08-24 NO NO20053947A patent/NO20053947L/no not_active Application Discontinuation
-
2009
- 2009-04-30 US US12/433,028 patent/US20090227490A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20060002778A (ko) | 2006-01-09 |
CN101579520A (zh) | 2009-11-18 |
EP1620117A2 (en) | 2006-02-01 |
AU2004220451B2 (en) | 2010-01-21 |
MXPA05009741A (es) | 2005-11-16 |
US7576188B2 (en) | 2009-08-18 |
NO20053947D0 (no) | 2005-08-24 |
NZ541634A (en) | 2008-08-29 |
CN1753684A (zh) | 2006-03-29 |
WO2004080421A2 (en) | 2004-09-23 |
RU2341283C2 (ru) | 2008-12-20 |
US20090227490A1 (en) | 2009-09-10 |
EP1620117A4 (en) | 2009-07-29 |
RU2005126819A (ru) | 2006-01-20 |
UA83022C2 (ru) | 2008-06-10 |
NO20053947L (no) | 2005-12-07 |
CN1761480A (zh) | 2006-04-19 |
US20060178298A1 (en) | 2006-08-10 |
CA2516572A1 (en) | 2004-09-23 |
CN100409895C (zh) | 2008-08-13 |
WO2004080421A3 (en) | 2005-06-09 |
AU2004220451A1 (en) | 2004-09-23 |
CN1761480B (zh) | 2012-09-26 |
JP2006519848A (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA82089C2 (ru) | Аплидин для лечения множественной миеломы | |
US10959984B2 (en) | Methods for treating cancer with RORγ inhibitors | |
US10039771B2 (en) | Method for cancer cell reprogramming | |
Sorrentino et al. | Therapeutic targeting of notch signaling pathway in hematological malignancies | |
IL170136A (en) | Apalidine-containing pharmaceutical preparations for use in common myeloma treatment | |
KR20110028454A (ko) | 다발성 골수종 치료법 | |
AU2023202746A1 (en) | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof | |
JP2003527441A (ja) | 細胞周期を阻止する薬剤及び抗体を含む医薬 | |
US8507443B2 (en) | Anticancer agent | |
CN116554357A (zh) | 一种双特异性嵌合抗原受体(car)及其在制备抗肿瘤药物中的应用 | |
CN110590850A (zh) | 一种抗急性髓系白血病的化合物及其制备方法与应用 | |
EP1002537A1 (en) | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma | |
CN111419832A (zh) | 药物组合物及其在制备治疗肿瘤药物中的用途 | |
Al-Odat | Selective Small Molecule Targeting of MCL-1 in Multiple Myeloma | |
AU2015242788B2 (en) | Anti-tumor drug containing taxane compound, and anti-tumor effect enhancer | |
WO2023210042A1 (ja) | Il-34を発現する腫瘍を治療および/または予防するための医薬 | |
CN110496223B (zh) | 一种治疗非霍奇金氏淋巴瘤的药物组合物 | |
Yu et al. | IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects | |
Van der Vreken et al. | Fueling CARs: metabolic strategies to enhance CAR T-cell therapy | |
Duan et al. | Cytotoxicity of lymphokine‐activated killer cells against human neuroblastoma cells: Modulation by neuroblast differentiation | |
CN115282280A (zh) | TGF-β1信号抑制剂的新用途 | |
CN116390735A (zh) | 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 | |
CN116173004A (zh) | 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途 | |
CN117122606A (zh) | 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒 | |
WO2019000327A1 (zh) | 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法 |